Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Source Type: research

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone
Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Authors: Alexa J. Loncharich, Mark A. Fiala, Michael J. Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark A. Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo Tags: Original Study Source Type: research

Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experience from the Amyloidosis Program of Calgary
Systemic light-chain amyloidosis (AL amyloidosis) is a proliferative clonal plasma cell disease caused by misfolded proteins forming toxic amyloid light-chain fibrils leading to organ damage.1 The backbone of treatment for transplant-ineligible AL amyloidosis has traditionally involved bortezomib-containing regimens (BCR).2,3 Recent studies involving AL amyloidosis have shown certain cytogenetic aberrations including t(11;14), are associated with sub-optimal responses to bortezomib and perhaps more novel agents such as daratumumab and venetoclax may yield better responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 17, 2023 Category: Hematology Authors: Ellen Lewis, Sylvia McCulloch, Etienne Mahe, Nizar Bahlis, Paola Neri, Jason Tay, Peter Duggan, Victor H Jimenez-Zepeda Tags: Letter to the Editor Source Type: research

Real-World Health Care Services Utilization Associated with the Management of Patients with Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization of health care services among the relapsed/refractory MM (RRMM) population are scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2023 Category: Hematology Authors: Enrique M. Ocio, Carmen Montes-Gais án, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez-Persona, Verónica González-Calle, Maialen Sirvent, José M. Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Al Tags: Original Study Source Type: research

Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service
This retrospective study included 353 patients with AML treated with CPX-351 in England. At median 10.9 months from diagnosis, median overall survival was 12.9 months and Day 30 all-cause mortality was 6% (17.3 vs. 11.7 months and 4% vs. 6%, respectively, for (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 10, 2023 Category: Hematology Authors: Alex Legg, Alexandrina Lambova, Anne Broe, Julia Levy, Greg Medalla Tags: Original Study Source Type: research

Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukaemia in England: An Analysis From the National Cancer Registration and Analysis Service
CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio.1 Since December 2018, the National Institute for Health and Care Excellence (NICE) has recommended the use of CPX-351 for adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) due either to a documented history of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML) prior to transformation to AML or to de novo AML with karyotypic changes characteristic of MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 10, 2023 Category: Hematology Authors: Alex Legg, Alexandrina Lambova, Anne Broe, Julia Levy, Greg Medalla Tags: Original Study Source Type: research

Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy into the Management of Newly Diagnosed Multiple Myeloma
Multiple myeloma is a hematologic malignancy that is typically associated with recurrent relapses. There are numerous frontline treatment regimens that are highly effective for individual patients. The introduction of anti-CD38 monoclonal antibody therapy has shifted treatment decision-making in this setting, with many centers now considering the use of daratumumab as part of initial therapy regardless of patient eligibility for autologous stem cell transplantation (ASCT). Daratumumab has demonstrated clinical efficacy and acceptable toxicity in the first and later lines of therapy, increasing complexity in treatment selec...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 10, 2023 Category: Hematology Authors: Sagar Lonial, Andrew D. Bowser, Ajai Chari, Caitlin Costello, Amrita Krishnan, Saad Z. Usmani Source Type: research

Factors influencing physician discretion to administer CNS prophylaxis in diffuse large B cell lymphoma: A single institution retrospective study
Central nervous system (CNS) relapse is an infrequent but serious and challenging complication in diffuse large B-cell lymphoma (DLBCL) that carries a dismal prognosis. While several risk factors have been identified to stratify the risk for CNS relapse including the 2015 CNS internal Prognostic index (CNS-IPI), controversy still remains regarding the indication, timing, and method of CNS prophylaxis. The purpose of this study was to determine whether IT-MTX reduced the risk of CNS relapse, as well as treatment related and financial toxicity of CNS prophylaxis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2023 Category: Hematology Authors: Christopher Hino, Curtis Lacy, Joel Brothers, Huynh Cao, Hamid Mirshahidi, Kiwon Park, Mojtaba Akhtari Tags: Original Study Source Type: research

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis
The Phase 3 IKEMA study (NCT03275285) demonstrated isatuximab (Isa) in combination with carfilzomib (K) and dexamethasone (d) significantly improved progression-free survival (PFS) in patients with relapsed multiple myeloma (MM) compared with Kd. A post-hoc analysis of East Asian patients in IKEMA evaluated the efficacy and safety of Isa-Kd versus Kd in this population and was previously published. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2023 Category: Hematology Authors: Yawara Kawano, Kihyun Kim, Chang Ki Min, Youngil Koh, Kenichi Ishizawa, Sung Hyun Kim, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Tadao Ishida, Jin Seok Kim, Philippe Moreau, Thomas Martin, Keisuke Tada, Marie-Laure Risse, Kenshi Suzuki Source Type: research

SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023.
The therapeutic landscape of Philadelphia chromosome positive acute lymphoblastic leukemia for adults has dramatically changed over the past two decades; the emergence of newer generations of tyrosine kinase inhibitors and incorporation of targeted immunotherapies into front-line therapy have significantly improved outcomes to the point where an argument can be made that this entity may no longer be considered a high-risk ALL subgroup. In this review article, we discuss different front-line regimens (both intensive and de-intensified regimens including chemotherapy-free regimens). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2023 Category: Hematology Authors: Zaid Abdel Rahman, Partow Kebriaei Tags: Original Study Source Type: research

Role of rituximab in treatment of patients with primary central nervous system lymphoma (PCNSL): A systematic review and meta-analysis
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cordand eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2023 Category: Hematology Authors: Yuhang Zhang, Zhihe Liu, Chengwen Gao, Haiyan Bian, Yushuo Ma, Fanjing Jing, Xia Zhao Tags: Review Article Source Type: research

Treatment Individualization in Diffuse Large B-cell Lymphoma: Is frailty enough for old adults? An original article
Indivualized treatment allocation based in previous toxicity risk is recommended in old adults diagnosed with hematologic malignancies. In our study we implemented a hypothetical treatment algorithm in 31 patients aged 70 years and recently diagnosed with Diffuse Large B-Cell Lymphoma based on information obtained in a comprehensive geriatric assessment at baseline. We observed that frailty assessment and physical performance evaluation measured by the functional score Short Physical Performance Battery are validated predictive factors suitable for risk stratification. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2023 Category: Hematology Authors: Agurne Garc ía-Baztán, Julio Oteiza-Olaso, Nancy Jeanette Gonzales-Montejo, Maria Fernanda Ramón-Espinoza, Ibai Tamayo-Rodríguez, Nicolás Martínez-Velilla, Mari Cruz Viguria-Alegria Tags: Original Study Source Type: research

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response by 18F-FDG PET/CT Imaging following CAR-T Therapy
CD19 directed Chimeric Antigen Receptor T-cell (CAR-T) therapy is now a commonly used treatment for relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) in cancer centers worldwide with initial response rates of 60-80% and with more than one-third achieving a durable remission. (1 –5) However, a source of clinical uncertainty has remained in patients with a partial response (PR) on day 28 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT). In the pivotal CAR-T clinical trials for LBCL, approximately half of these patients eventually achie ved a complete remission (CR), while the othe...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2023 Category: Hematology Authors: Forat Lutfi, Olga Goloubeva, Amer Kowatli, Anton Gryaznov, Dong W Kim, Rohan Dureja, Philip Margiotta, Lisa R Matsumoto, Ali Bukhari, Nausheen Ahmed, Muhammad Umair Mushtaq, Jennie Y. Law, Seung T. Lee, Mehmet H. Kocoglu, Djordje Atanackovic, Jean A. Yare Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 17, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 17, 2023 Category: Hematology Source Type: research